A carregar...

Biomarker‐guided clinical development of the first‐in‐class anti‐inflammatory FPR2/ALX agonist ACT‐389949

AIMS: The main objectives of these two phase I studies were to investigate safety and tolerability as well as the pharmacokinetic/pharmacodynamic profile of the novel potent and selective formyl peptide receptor type 2 (FPR2)/Lipoxin A(4) receptor (ALX) agonist ACT‐389949. A challenge model was used...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Clin Pharmacol
Main Authors: Stalder, Anna K., Lott, Dominik, Strasser, Daniel S., Cruz, Hans G., Krause, Andreas, Groenen, Peter M.A., Dingemanse, Jasper
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2016
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5306489/
https://ncbi.nlm.nih.gov/pubmed/27730665
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13149
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!